Bio-Behavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-Life Database Analysis Article Swipe
Boris Kovatchev
,
Harsimran Singh
,
Lars Müeller
,
Linda Gonder‐Frederick
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.2337/figshare.20645448.v1
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.2337/figshare.20645448.v1
Objective: Document glycemic and user-initiated bolus changes following transition from predictive-low glucose suspend (PLGS) system to automated insulin delivery (AID) system during real-life use. Research Design and Methods: Analysis of 2,329,166 days (6,381 patient-years) of continuous glucose monitoring (CGM) and insulin therapy data for 19,354 individuals with Type 1 Diabetes, during 1-month PLGS (Basal-IQ technology) use followed by 3-month AID use (Control-IQ technology). Baseline characteristics: 55.4 percent female, age (median/quartiles/range) 39/19-58/1-92 years, glucose management indicator (GMI) 7.5±0.8. Primary outcome: time in target range (TIR 70-180mg/dL). Secondary outcomes: CGM-based glycemic control metrics; frequency of user-initiated boluses. Results: Compared to PLGS, AID increased TIR on average from 58.4 to 70.5 percent. GMI and percent time above/below target range improved as well, 7.5 to 7.1; 39.9 to 28.1 percent, and 1.66 to 1.46 percent, respectively, all p-levels <0.0001. Stratification of outcomes by age and baseline GMI revealed clinically significant differences. Glycemic improvements were most pronounced in those 8.0 (TIR improvement 13.2 percentage points). User-initiated correction boluses decreased from 2.7 to 1.8 per day, while user-initiated meal boluses remained stable at 3.6 to 3.8 per day. Conclusions: Observed in real life of over 19,000 individuals with type 1 diabetes, transitions from PLGS to AID resulted in improvement of all glycemic parameters, equivalent to improvements observed in randomized clinical trials, and reduced user-initiated boluses. However, glycemic and behavioral changes with AID use may differ greatly across different demographic and clinical groups.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.2337/figshare.20645448.v1
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4296493343
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4296493343Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.2337/figshare.20645448.v1Digital Object Identifier
- Title
-
Bio-Behavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-Life Database AnalysisWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-09-20Full publication date if available
- Authors
-
Boris Kovatchev, Harsimran Singh, Lars Müeller, Linda Gonder‐FrederickList of authors in order
- Landing page
-
https://doi.org/10.2337/figshare.20645448.v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.2337/figshare.20645448.v1Direct OA link when available
- Concepts
-
Glycemic, Medicine, Quartile, Insulin, Type 1 diabetes, Insulin delivery, Internal medicine, Diabetes mellitus, Endocrinology, Confidence intervalTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4296493343 |
|---|---|
| doi | https://doi.org/10.2337/figshare.20645448.v1 |
| ids.doi | https://doi.org/10.2337/figshare.20645448.v1 |
| ids.openalex | https://openalex.org/W4296493343 |
| fwci | 0.0 |
| type | preprint |
| title | Bio-Behavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-Life Database Analysis |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10560 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9973999857902527 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Diabetes Management and Research |
| topics[1].id | https://openalex.org/T10401 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9373999834060669 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2712 |
| topics[1].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[1].display_name | Diabetes Treatment and Management |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780473172 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7654471397399902 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q5572518 |
| concepts[0].display_name | Glycemic |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6753168106079102 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C68443243 |
| concepts[2].level | 3 |
| concepts[2].score | 0.588993489742279 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2786686 |
| concepts[2].display_name | Quartile |
| concepts[3].id | https://openalex.org/C2779306644 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5258638858795166 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2002370 |
| concepts[3].display_name | Insulin |
| concepts[4].id | https://openalex.org/C2781232474 |
| concepts[4].level | 3 |
| concepts[4].score | 0.4949011206626892 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q124407 |
| concepts[4].display_name | Type 1 diabetes |
| concepts[5].id | https://openalex.org/C2994527087 |
| concepts[5].level | 4 |
| concepts[5].score | 0.4320254921913147 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2002370 |
| concepts[5].display_name | Insulin delivery |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.41918790340423584 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C555293320 |
| concepts[7].level | 2 |
| concepts[7].score | 0.370816171169281 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[7].display_name | Diabetes mellitus |
| concepts[8].id | https://openalex.org/C134018914 |
| concepts[8].level | 1 |
| concepts[8].score | 0.2982673645019531 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[8].display_name | Endocrinology |
| concepts[9].id | https://openalex.org/C44249647 |
| concepts[9].level | 2 |
| concepts[9].score | 0.08941072225570679 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[9].display_name | Confidence interval |
| keywords[0].id | https://openalex.org/keywords/glycemic |
| keywords[0].score | 0.7654471397399902 |
| keywords[0].display_name | Glycemic |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.6753168106079102 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/quartile |
| keywords[2].score | 0.588993489742279 |
| keywords[2].display_name | Quartile |
| keywords[3].id | https://openalex.org/keywords/insulin |
| keywords[3].score | 0.5258638858795166 |
| keywords[3].display_name | Insulin |
| keywords[4].id | https://openalex.org/keywords/type-1-diabetes |
| keywords[4].score | 0.4949011206626892 |
| keywords[4].display_name | Type 1 diabetes |
| keywords[5].id | https://openalex.org/keywords/insulin-delivery |
| keywords[5].score | 0.4320254921913147 |
| keywords[5].display_name | Insulin delivery |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.41918790340423584 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[7].score | 0.370816171169281 |
| keywords[7].display_name | Diabetes mellitus |
| keywords[8].id | https://openalex.org/keywords/endocrinology |
| keywords[8].score | 0.2982673645019531 |
| keywords[8].display_name | Endocrinology |
| keywords[9].id | https://openalex.org/keywords/confidence-interval |
| keywords[9].score | 0.08941072225570679 |
| keywords[9].display_name | Confidence interval |
| language | en |
| locations[0].id | doi:10.2337/figshare.20645448.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by-nc-sa |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-sa |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.2337/figshare.20645448.v1 |
| locations[1].id | pmh:oai:figshare.com:article/20645448 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306400572 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | OPAL (Open@LaTrobe) (La Trobe University) |
| locations[1].source.host_organization | https://openalex.org/I196829312 |
| locations[1].source.host_organization_name | La Trobe University |
| locations[1].source.host_organization_lineage | https://openalex.org/I196829312 |
| locations[1].license | cc-by-nc-sa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Image |
| locations[1].license_id | https://openalex.org/licenses/cc-by-nc-sa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://figshare.com/articles/figure/Bio-Behavioral_Changes_Following_Transition_to_Automated_Insulin_Delivery_A_Large_Real-Life_Database_Analysis/20645448 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5075609104 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-0495-3901 |
| authorships[0].author.display_name | Boris Kovatchev |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Boris P. Kovatchev |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5066959048 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6645-3115 |
| authorships[1].author.display_name | Harsimran Singh |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Harsimran Singh |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5111791856 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Lars Müeller |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Lars Mueller |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5068295948 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3009-2626 |
| authorships[3].author.display_name | Linda Gonder‐Frederick |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Linda A. Gonder-Frederick |
| authorships[3].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.2337/figshare.20645448.v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Bio-Behavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-Life Database Analysis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10560 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9973999857902527 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Diabetes Management and Research |
| related_works | https://openalex.org/W2017030704, https://openalex.org/W3010475752, https://openalex.org/W3214191526, https://openalex.org/W2043682428, https://openalex.org/W4226100589, https://openalex.org/W15769231, https://openalex.org/W2087490161, https://openalex.org/W3023104103, https://openalex.org/W1965724144, https://openalex.org/W2136287298 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.2337/figshare.20645448.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by-nc-sa |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-sa |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.2337/figshare.20645448.v1 |
| primary_location.id | doi:10.2337/figshare.20645448.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by-nc-sa |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-sa |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.2337/figshare.20645448.v1 |
| publication_date | 2022-09-20 |
| publication_year | 2022 |
| referenced_works_count | 0 |
| abstract_inverted_index.1 | 50, 208 |
| abstract_inverted_index.as | 119 |
| abstract_inverted_index.at | 191 |
| abstract_inverted_index.by | 59, 140 |
| abstract_inverted_index.in | 82, 154, 199, 216, 226 |
| abstract_inverted_index.of | 31, 36, 94, 138, 202, 218 |
| abstract_inverted_index.on | 104 |
| abstract_inverted_index.to | 17, 99, 108, 122, 125, 130, 181, 193, 213, 223 |
| abstract_inverted_index.1.8 | 182 |
| abstract_inverted_index.2.7 | 180 |
| abstract_inverted_index.3.6 | 192 |
| abstract_inverted_index.3.8 | 194 |
| abstract_inverted_index.7.5 | 121 |
| abstract_inverted_index.AID | 61, 101, 214, 240 |
| abstract_inverted_index.GMI | 111, 144, 168 |
| abstract_inverted_index.TIR | 103 |
| abstract_inverted_index.age | 70, 141 |
| abstract_inverted_index.all | 134, 219 |
| abstract_inverted_index.and | 5, 28, 41, 112, 128, 142, 164, 230, 236, 248 |
| abstract_inverted_index.for | 45 |
| abstract_inverted_index.may | 242 |
| abstract_inverted_index.old | 158 |
| abstract_inverted_index.per | 183, 195 |
| abstract_inverted_index.use | 57, 62, 241 |
| abstract_inverted_index.(TIR | 85, 159, 170 |
| abstract_inverted_index.1.46 | 131 |
| abstract_inverted_index.1.66 | 129 |
| abstract_inverted_index.13.2 | 172 |
| abstract_inverted_index.14.0 | 161 |
| abstract_inverted_index.28.1 | 126 |
| abstract_inverted_index.39.9 | 124 |
| abstract_inverted_index.55.4 | 67 |
| abstract_inverted_index.58.4 | 107 |
| abstract_inverted_index.7.1; | 123 |
| abstract_inverted_index.70.5 | 109 |
| abstract_inverted_index.PLGS | 54, 212 |
| abstract_inverted_index.Type | 49 |
| abstract_inverted_index.data | 44 |
| abstract_inverted_index.day, | 184 |
| abstract_inverted_index.days | 33 |
| abstract_inverted_index.from | 11, 106, 179, 211 |
| abstract_inverted_index.life | 201 |
| abstract_inverted_index.meal | 187 |
| abstract_inverted_index.most | 152 |
| abstract_inverted_index.over | 203 |
| abstract_inverted_index.real | 200 |
| abstract_inverted_index.time | 81, 114 |
| abstract_inverted_index.type | 207 |
| abstract_inverted_index.were | 151 |
| abstract_inverted_index.with | 48, 166, 206, 239 |
| abstract_inverted_index.(AID) | 21 |
| abstract_inverted_index.(CGM) | 40 |
| abstract_inverted_index.(GMI) | 77 |
| abstract_inverted_index.PLGS, | 100 |
| abstract_inverted_index.bolus | 7 |
| abstract_inverted_index.range | 84, 117 |
| abstract_inverted_index.those | 155, 165 |
| abstract_inverted_index.well, | 120 |
| abstract_inverted_index.while | 185 |
| abstract_inverted_index.years | 157 |
| abstract_inverted_index.<18 | 156 |
| abstract_inverted_index.(6,381 | 34 |
| abstract_inverted_index.(PLGS) | 15 |
| abstract_inverted_index.19,000 | 204 |
| abstract_inverted_index.19,354 | 46 |
| abstract_inverted_index.Design | 27 |
| abstract_inverted_index.across | 245 |
| abstract_inverted_index.differ | 243 |
| abstract_inverted_index.during | 23, 52 |
| abstract_inverted_index.stable | 190 |
| abstract_inverted_index.system | 16, 22 |
| abstract_inverted_index.target | 83, 116 |
| abstract_inverted_index.years, | 73 |
| abstract_inverted_index.>8.0 | 169 |
| abstract_inverted_index.1-month | 53 |
| abstract_inverted_index.3-month | 60 |
| abstract_inverted_index.Primary | 79 |
| abstract_inverted_index.average | 105 |
| abstract_inverted_index.boluses | 177, 188 |
| abstract_inverted_index.changes | 8, 238 |
| abstract_inverted_index.control | 91 |
| abstract_inverted_index.female, | 69 |
| abstract_inverted_index.glucose | 13, 38, 74 |
| abstract_inverted_index.greatly | 244 |
| abstract_inverted_index.groups. | 250 |
| abstract_inverted_index.insulin | 19, 42 |
| abstract_inverted_index.percent | 68, 113 |
| abstract_inverted_index.reduced | 231 |
| abstract_inverted_index.suspend | 14 |
| abstract_inverted_index.therapy | 43 |
| abstract_inverted_index.trials, | 229 |
| abstract_inverted_index.Analysis | 30 |
| abstract_inverted_index.Baseline | 65 |
| abstract_inverted_index.Compared | 98 |
| abstract_inverted_index.Document | 3 |
| abstract_inverted_index.Glycemic | 149 |
| abstract_inverted_index.However, | 234 |
| abstract_inverted_index.Observed | 198 |
| abstract_inverted_index.baseline | 143, 167 |
| abstract_inverted_index.boluses. | 233 |
| abstract_inverted_index.clinical | 228, 249 |
| abstract_inverted_index.delivery | 20 |
| abstract_inverted_index.followed | 58 |
| abstract_inverted_index.glycemic | 4, 90, 220, 235 |
| abstract_inverted_index.improved | 118 |
| abstract_inverted_index.metrics; | 92 |
| abstract_inverted_index.observed | 225 |
| abstract_inverted_index.outcome: | 80 |
| abstract_inverted_index.outcomes | 139 |
| abstract_inverted_index.p-levels | 135 |
| abstract_inverted_index.percent, | 127, 132 |
| abstract_inverted_index.percent. | 110 |
| abstract_inverted_index.points), | 163 |
| abstract_inverted_index.points). | 174 |
| abstract_inverted_index.remained | 189 |
| abstract_inverted_index.resulted | 215 |
| abstract_inverted_index.revealed | 145 |
| abstract_inverted_index.<p> | 0 |
| abstract_inverted_index.(Basal-IQ | 55 |
| abstract_inverted_index.2,329,166 | 32 |
| abstract_inverted_index.7.5±0.8. | 78 |
| abstract_inverted_index.CGM-based | 89 |
| abstract_inverted_index.Diabetes, | 51 |
| abstract_inverted_index.Secondary | 87 |
| abstract_inverted_index.automated | 18 |
| abstract_inverted_index.decreased | 178 |
| abstract_inverted_index.diabetes, | 209 |
| abstract_inverted_index.different | 246 |
| abstract_inverted_index.following | 9 |
| abstract_inverted_index.frequency | 93 |
| abstract_inverted_index.increased | 102 |
| abstract_inverted_index.indicator | 76 |
| abstract_inverted_index.outcomes: | 88 |
| abstract_inverted_index.real-life | 24 |
| abstract_inverted_index.</p> | 1, 251 |
| abstract_inverted_index.behavioral | 237 |
| abstract_inverted_index.clinically | 146 |
| abstract_inverted_index.continuous | 37 |
| abstract_inverted_index.correction | 176 |
| abstract_inverted_index.equivalent | 222 |
| abstract_inverted_index.management | 75 |
| abstract_inverted_index.monitoring | 39 |
| abstract_inverted_index.percentage | 162, 173 |
| abstract_inverted_index.pronounced | 153 |
| abstract_inverted_index.randomized | 227 |
| abstract_inverted_index.transition | 10 |
| abstract_inverted_index.<0.0001. | 136 |
| abstract_inverted_index.(Control-IQ | 63 |
| abstract_inverted_index.above/below | 115 |
| abstract_inverted_index.demographic | 247 |
| abstract_inverted_index.improvement | 160, 171, 217 |
| abstract_inverted_index.individuals | 47, 205 |
| abstract_inverted_index.parameters, | 221 |
| abstract_inverted_index.significant | 147 |
| abstract_inverted_index.technology) | 56 |
| abstract_inverted_index.transitions | 210 |
| abstract_inverted_index.differences. | 148 |
| abstract_inverted_index.improvements | 150, 224 |
| abstract_inverted_index.technology). | 64 |
| abstract_inverted_index.39/19-58/1-92 | 72 |
| abstract_inverted_index.70-180mg/dL). | 86 |
| abstract_inverted_index.respectively, | 133 |
| abstract_inverted_index.Stratification | 137 |
| abstract_inverted_index.User-initiated | 175 |
| abstract_inverted_index.day.</p> | 196 |
| abstract_inverted_index.patient-years) | 35 |
| abstract_inverted_index.predictive-low | 12 |
| abstract_inverted_index.use.</p> | 25 |
| abstract_inverted_index.user-initiated | 6, 95, 186, 232 |
| abstract_inverted_index.characteristics: | 66 |
| abstract_inverted_index.Methods:</u> | 29 |
| abstract_inverted_index.boluses.</p> | 96 |
| abstract_inverted_index.(median/quartiles/range) | 71 |
| abstract_inverted_index.<p><u>Research | 26 |
| abstract_inverted_index.<p><u>Results</u>: | 97 |
| abstract_inverted_index.<p><u>Objective:</u> | 2 |
| abstract_inverted_index.<p><u>Conclusions:</u> | 197 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 4 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/12 |
| sustainable_development_goals[0].score | 0.4399999976158142 |
| sustainable_development_goals[0].display_name | Responsible consumption and production |
| citation_normalized_percentile.value | 0.19616153 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |